Akari Therapeutics, Plc announced that it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), with Part A data expected in the first half of 2023, and to the promising pre-clinical program of PAS-nomacopan in geographic atrophy (GA) that has generated positive pre-clinical results. Akari is discontinuing the clinical program evaluating nomacopan in bullous pemphigoid (BP). The decision to narrow the pipeline focus is based on Akari's thorough reassessment of development timelines and associated costs to maximize value in its pipeline.

It is not related to BP clinical trial data and the company is not restructuring or reducing headcount.